同种异体子宫内膜异位症大鼠模型用于GnRH激动剂类药物的药效评价研究

doi:10.12300/j.issn.1674-5817.2023.150

实验动物与比较医学 ›› 2024, Vol. 44 ›› Issue (2): 127-138.DOI: 10.12300/j.issn.1674-5817.2023.150

• 人类疾病动物模型 • 下一篇

同种异体子宫内膜异位症大鼠模型用于GnRH激动剂类药物的药效评价研究

钟瑞华¹, 李国停¹, 杨文捷¹, 郭湘洁¹, 周洁芸¹, 胡颖怡¹, 倪其承¹^,², 杨野¹^,², 张敏³, 朱焰¹()()

^1.国家卫生健康委员会生育调节药械重点实验室, 上海生殖健康药具工程技术研究中心, 上海市生物医药技术研究院生殖药理组, 上海 200237
^2.复旦大学药学院, 上海 200032
^3.长春金赛药业有限公司, 长春 130012

收稿日期:2023-11-03 修回日期:2024-02-01 出版日期:2024-04-25 发布日期:2024-04-25
通讯作者: 朱焰（1970—），女，博士，研究员，从事生殖药理学研究。E-mail： zhuyan@sippr.org。ORCID： 0000-0001-5136-7601
作者简介:钟瑞华（1988—），女，硕士，助理研究员，从事生殖药理学研究。E-mail： zrh8804@126.com

Application of Allograft Endometriosis Rat Model in Pharmaco-dynamic Evaluation of GnRH Agonists

Ruihua ZHONG¹, Guoting LI¹, Wenjie YANG¹, Xiangjie GUO¹, Jieyun ZHOU¹, Yingyi HU¹, Qicheng NI¹^,², Ye YANG¹^,², Min ZHANG³, Yan ZHU¹()()

^1.NHC Key Laboratory of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies Laboratory of Reproductive Pharmacology, Shanghai 200237, China
^2.Pharmacy School, Fudan University, Shanghai 200032, China
^3.Changchun Gene Science Pharmaceutical Co. , Ltd. , Changchun 130012, China

Received:2023-11-03 Revised:2024-02-01 Published:2024-04-25 Online:2024-04-25
Contact: ZHU Yan (ORCID:0000-0001-5136-7601), E-mail: zhuyan@sippr.org

摘要/Abstract

摘要：

目的用同种异体移植的方法构建大鼠子宫内膜异位症模型，并评价促性腺激素释放激素（gonadotropin-releasing hormone，GnRH）激动剂GenSci006对实验大鼠子宫内膜异位症模型的影响。方法取供体SPF级雌性SD大鼠的子宫内膜移植于受体雌性大鼠的腹腔壁上，构建同种异体的子宫内膜异位症模型。3周后，测量异位内膜的长、宽、高，计算给药前异位内膜的体积V₁。将进行假手术操作的大鼠设为假手术组，将造模大鼠随机分为模型组、曲普瑞林组（0.25 mg/kg）、GenSci006-1组（0.125 mg/kg）和GenSci006-2组（0.25 mg/kg）共4组，每组大鼠16只。各组大鼠单次给予相应的药物，假手术组和模型组给予同等体积的溶剂。3周后，再次测量异位内膜，计算给药后异位内膜的体积V₂和抑制率；通过比较脏器系数及病理切片的变化，判断GenSci006 对大鼠子宫和卵巢组织的影响；ELISA法测定血清中雌二醇（estradiol，E₂）、孕酮（progesterone，P₄）、卵泡刺激素（follicle stimulating hormone，FSH）和黄体生成素（luteinizing hormone，LH）水平的变化；实时荧光定量PCR法测定下丘脑和垂体中GnRH受体（GnRH receptor，GnRHR）mRNA的表达水平。蛋白质印迹法检测异位内膜组织中雌激素受体（estrogen receptor，ER）α、ERβ和孕激素受体（progesterone receptor，PR）蛋白的表达。结果给药3周后发现，与模型组相比，曲普瑞林组和GenSci006-2组大鼠的体重显著增加（P<0.05），而异位内膜的体积显著减小（P<0.05）。与假手术组相比，模型组子宫、卵巢脏器系数及子宫内膜厚度无明显变化（P>0.05）；与模型组相比，曲普瑞林组和GenSci006-2组子宫脏器系数及子宫内膜厚度显著降低（P<0.05）。与假手术组相比，模型组血清中E₂、P₄、FSH、LH水平无明显变化（P>0.05）；与模型组相比，曲普瑞林组、GenSci006-1组和GenSci006-2组大鼠的卵巢脏器系数和血清P₄水平均显著降低（P<0.05），而GenSci006-1组大鼠的血清LH水平明显升高（P<0.05），但各组血清E₂和FSH水平并无显著变化（P>0.05）。与模型组相比，曲普瑞林组和GenSci006-2组大鼠垂体GnRHR mRNA表达水平显著下调（P<0.05）；各组大鼠下丘脑组织中GnRHR mRNA表达及异位内膜组织中ERα、ERβ、PR蛋白表达水平无明显变化（P>0.05）。结论大鼠同种异体子宫内膜异位症模型适宜作为筛选和评价子宫内膜异位症治疗药物的动物模型，而且异位内膜体积、抑制率、子宫及卵巢脏器系数、血清E₂水平均可作为检测药物疗效的指标。

关键词: 子宫内膜异位症, GenSci006, 曲普瑞林, 异位内膜, 大鼠

Abstract:

Objective To establish an allogeneic rat model of endometriosis and to evaluate the effects of gonadotropin-releasing hormone (GnRH) agonist GenSci006 on experimental rat endometriosis. Methods Endometrium from SPF grade donor female SD rats were transplanted onto the abdominal wall of recipient female rats to construct an allogeneic endometriosis model. The rats undergoing sham surgery were divided into the sham group. Three weeks later, the length, width and height of the ectopic endometrium were measured, and the volume of the endometrium (V₁) was calculated before drug administration. The modeling rats were randomly divided into four groups: model group, triptorelin group (0.25 mg/kg), GenSci006-1 group (0.125 mg/kg) and GenSci006-2 group (0.25 mg/kg). Each group had 16 rats and received a single dose of the corresponding drug. The sham group and model group were administered an equal volume of solvent. Three weeks after administration, ectopic endometrium was measured to calculate the volume V₂ and inhibition rate. The effect of GenSci006 on rat uterus and ovarian tissues was assessed by comparing organ coefficients and changes in pathological sections. Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of serum estradiol (E₂), progesterone (P₄), follicle stimulating hormone (FSH), and luteinizing hormone (LH). Real-time fluorescent quantitative PCR was used to detect the expression of GnRH receptor (GnRHR) mRNA in the hypothalamus and pituitary. Western blot was used to detect the expression of estradiol receptor alpha (ERα), beta (ERβ) and progesterone receptor (PR) in ectopic endometrium. Results Three weeks after administration, compared with the model group, the body weight of rats in the triptorelin and GenSci006-2 groups significantly increased (P < 0.05), while the volume of ectopic endometrium significantly decreased (P < 0.05). Compared with the sham group, the model group showed no significant changes in uterine and ovarian organ coefficients or endometrial thickness (P > 0.05). Compared with the model group, the uterine organ coefficients and endometrial thickness were significantly reduced in the triptorelin and GenSci006-2 groups (P < 0.05). Compared with the sham group, the serum levels of E₂, P₄, FSH and LH in the model group showed no significant changes (P > 0.05). Compared with the model group, the ovarian organ coefficient and serum P₄ levels of rats in the Triptorelin, GenSci006-1, and GenSci006-2 groups were significantly reduced (P < 0.05), while the serum LH levels of rats in the GenSci006-1 group were significantly increased (P < 0.05). However, there were no significant changes in serum E₂ and FSH levels in each group (P > 0.05). Compared with the model group, the expression levels of GnRHR mRNA in the pituitary tissue of rats in the triptorelin and GenSci006-2 groups were significantly downregulated (P < 0.05), with no significantly changes in the hypothalamus (P > 0.05). There were no significant changes in the expression level of GnRHR mRNA in the hypothalamus or the protein levels of ERα, ERβ and PR in the ectopic endometrial tissue in any group (P > 0.05). Conclusion The allogeneic endometriosis rat model is a suitable animal model for screening and evaluating drugs for treating endometriosis. The volume of ectopic endometrium, inhibition rate, uterine and ovarian organ coefficients, and serum E₂ levels may serve as indicators for detecting drug efficacy.

Key words: Endometriosis, GenSci006, Triptorelin, Ectopic endometrium, Rat

中图分类号:

R-332

钟瑞华,李国停,杨文捷,等. 同种异体子宫内膜异位症大鼠模型用于GnRH激动剂类药物的药效评价研究[J]. 实验动物与比较医学, 2024, 44(2): 127-138. DOI: 10.12300/j.issn.1674-5817.2023.150.

Ruihua ZHONG,Guoting LI,Wenjie YANG,et al. Application of Allograft Endometriosis Rat Model in Pharmaco-dynamic Evaluation of GnRH Agonists[J]. Laboratory Animal and Comparative Medicine, 2024, 44(2): 127-138. DOI: 10.12300/j.issn.1674-5817.2023.150.

图/表 6

图1 GenSci006对同种异体移植子宫异位内膜症模型大鼠体重的影响注：Sham即假手术组，移植同种异体子宫周围的脂肪到大鼠腹壁，然后注射GenSci006专用溶剂；Model即模型组，移植同种异体子宫内膜组织到大鼠腹壁，然后注射GenSci006专用溶剂；Triptorelin即曲普瑞林组，移植同种异体子宫内膜组织到大鼠腹壁，然后注射曲普瑞林0.25 mg/kg；GenSci006-1和GenSci006-2组，移植同种异体子宫内膜组织到大鼠腹壁，然后分别注射0.125 mg/kg和 0.25 mg/kg的GenSci006。每组16只大鼠；与模型组相比，*P<0.05。

Figure 1 Effect of GenSci006 on body weight of allograft endometriosis rat modelNote：Sham group （n=16）， transplanted with fat tissues around the uterus and injected with GenSci006 specific solvent； Model group （n=16）， xenografted with endometrial tissues and injected with GenSci006 specific solvent； Triptorelin group（n=16）， xenografted with endometrial tissues and injected with 0.25 mg/kg triptorelin； GenSci006-1 and GenSci006-2 groups （each n=16）， xenografted with endometrial tissues and injected with 0.125 mg/kg and 0.25 mg/kg GenSci006， respectively. Compared with the model group， * P<0.05.

图2 GenSci006对同种异体移植子宫内膜异位症模型大鼠异位内膜的抑制作用注：A，给药前各组大鼠的异位内膜图片；B，给药后各组大鼠的异位内膜图片；C，给药3周后各组大鼠的异位内膜病理学特征（HE染色，×10）；D，给药前、后各组大鼠的异位内膜体积及抑制率。Sham即假手术组，移植同种异体子宫周围的脂肪到大鼠腹壁，然后注射GenSci006专用溶剂；Model即模型组，移植同种异体子宫内膜组织到大鼠腹壁，然后注射GenSci006专用溶剂；Triptorelin即曲普瑞林组，移植同种异体子宫内膜组织到大鼠腹壁，然后注射曲普瑞林0.25 mg/kg；GenSci006-1和GenSci006-2组，移植同种异体子宫内膜组织到大鼠腹壁，然后分别注射0.125 mg/kg和 0.25 mg/kg的GenSci006。每组16只大鼠；与模型组相比，*P<0.05。

Figure 2 Inhibitory effect of GenSci006 on ectopic endometrium in allograft endometriosis ratsNote： A， Pictures of ectopic endometrium before administration； B， Pictures of ectopic endometrium after administration；C， Pathological section of ectopic endometrium in endometriosis model rats（HE staining， ×10）；D， Tthe volume of ectopic endometrium before and after administration and the inhibition rate. Sham group （n=16）， transplanted with fat tissues around the uterus and injected with GenSci006 specific solvent； Model group （n=16）， xenografted with endometrial tissues and injected with GenSci006 specific solvent； Triptorelin group （n=16）， xenografted with endometrial tissues and injected with 0.25 mg/kg triptorelin； GenSci006-1 and GenSci006-2 groups （each n=16）， xenografted with endometrial tissues and injected with 0.125 mg/kg and 0.25 mg/kg GenSci006， respectively. Compared with the model group，*P<0.05.

图3 GenSci006对同种异体移植子宫内膜异位症模型大鼠子宫和卵巢的影响注：A示子宫组织病理切片（×10）；B示卵巢组织病理切片（×10），箭头所指处为生长卵泡；C示子宫、卵巢脏器系数和子宫组织的内膜厚度。Sham即假手术组，移植同种异体子宫周围的脂肪到大鼠腹壁，然后注射GenSci006专用溶剂；Model即模型组，移植同种异体子宫内膜组织到大鼠腹壁，然后注射GenSci006专用溶剂；Triptorelin即曲普瑞林组，移植同种异体子宫内膜组织到大鼠腹壁，然后注射曲普瑞林0.25 mg/kg；GenSci006-1和GenSci006-2组，移植同种异体子宫内膜组织到大鼠腹壁，然后分别注射0.125 mg/kg和 0.25 mg/kg的GenSci006。每组16只大鼠；与模型组相比，*P<0.05。

Figure 3 Effect of GenSci006 on uterus and ovary in allograft endometriosis ratsNote：A， Pathological section of uterus in endometriosis model rats （HE staining， ×10）；B， Ppathological section of ovary in endometriosis model rats （HE staining， ×10）； The arrow represents growth follicles；C， The coefficient of uterine organs，endometrial thickness and ovarian organ coefficient. Sham group （n=16）， transplanted with fat tissues around the uterus and injected with GenSci006 specific solvent； Model group （n=16）， xenografted with endometrial tissues and injected with GenSci006 specific solvent； Triptorelin group （n=16）， xenografted with endometrial tissues and injected with 0.25 mg/kg triptorelin； GenSci006-1 and GenSci006-2 groups （each n=16）， xenografted with endometrial tissues and injected with 0.125 mg/kg and 0.25 mg/kg GenSci006， respectively. Compared with the model group，*P<0.05

图 4 GenSci006对同种异体移植子宫内膜异位症模型大鼠血清E2、P4、FSH和LH水平的影响注：A，血清中雌二醇（E2 ）水平；B，血清中孕酮（P4）水平；C，血清中卵泡刺激素（FSH）水平；D，血清中黄体生成素（LH）水平。Sham即假手术组，移植同种异体子宫周围的脂肪到大鼠腹壁，然后注射GenSci006专用溶剂；Model即模型组，移植同种异体子宫内膜组织到大鼠腹壁，然后注射GenSci006专用溶剂；Triptorelin即曲普瑞林组，移植同种异体子宫内膜组织到大鼠腹壁，然后注射曲普瑞林0.25 mg/kg；GenSci006-1和GenSci006-2组，移植同种异体子宫内膜组织到大鼠腹壁，然后分别注射0.125 mg/kg和 0.25 mg/kg的GenSci006。每组8只大鼠；与模型组相比，*P<0.05；与曲普瑞林组相比，#P<0.05。

Figure 4 Effect of GenSci006 on serum levels of E2， P4， FSH and LH in allograft endometriosis ratsNote： A， Serum level of estradiol （E2）； B， Serum level of progesterone （P4）； C， Serum level of follicle stimulating hormone （FSH）； D， Serum level of luteinizing hormone （LH）. Sham group （n=8）， transplanted with fat tissues and injected with GenSci006 specific solvent； Model group （n=8）， xenografted with endometrial tissues around the uterus and injected with GenSci006 specific solvent； Triptorelin group （n=8）， xenografted with endometrial tissues and injected with 0.25 mg/kg triptorelin； GenSci006-1 and GenSci006-2 groups （each n=8）， xenografted with endometrial tissues and injected with 0.125 mg/kg and 0.25 mg/kg GenSci006， respectively. Compared with the model group， *P<0.05； Compared with the triptorelin group， #P<0.05.

图5 GenSci006对同种异体移植子宫内膜异位症模型大鼠下丘脑和垂体组织中GnRHR基因mRNA表达水平的影响注：A，下丘脑组织中促性腺激素释放激素受体（GnRHR） mRNA 表达；B，垂体组织中GnRHR mRNA 表达。Sham即假手术组，移植同种异体子宫周围的脂肪到大鼠腹壁，然后注射GenSci006专用溶剂；Model即模型组，移植同种异体子宫内膜组织到大鼠腹壁，然后注射GenSci006专用溶剂；Triptorelin即曲普瑞林组，移植同种异体子宫内膜组织到大鼠腹壁，然后注射曲普瑞林0.25 mg/kg；GenSci006-1和GenSci006-2组，移植同种异体子宫内膜组织到大鼠腹壁，然后分别注射0.125 mg/kg和 0.25 mg/kg的GenSci006。每组6只大鼠；与模型组相比，*P<0.05。

Figure 5 Effect of GenSci006 on GnRHR mRNA expression in hypothalamus and pituitary of allograft endometriosis ratsNote： A， Gonadotropin-releasing hormone receptor （GnRHR） mRNA expression in hypothalamus； B， GnRHR mRNA expression in pituitary. Sham group （n=6）， transplanted with fat tissues and injected with GenSci006 specific solvent； Model group （n=6）， xenografted with endometrial tissues around the uterus and injected with GenSci006 specific solvent； Triptorelin group （n=6）， xenografted with endometrial tissues and injected with 0.25 mg/kg triptorelin； GenSci006-1 and GenSci006-2 groups （each n=6）， xenografted with endometrial tissues and injected with 0.125 mg/kg and 0.25 mg/kg GenSci006， respectively. Compared with the model group， *P<0.05.

图6 GenSci006对同种异体移植子宫内膜异位症模型大鼠异位内膜组织中ERα、ERβ、PR蛋白表达的影响注：ERα/β，雌激素受体α/β；PR，孕激素受体。Model即模型组，移植同种异体子宫内膜组织到大鼠腹壁，然后注射GenSci006专用溶剂；Triptorelin即曲普瑞林组，移植同种异体子宫内膜组织到大鼠腹壁，然后注射曲普瑞林0.25 mg/kg；GenSci006-1和GenSci006-2组，移植同种异体子宫内膜组织到大鼠腹壁，然后分别注射0.125 mg/kg和 0.25 mg/kg的GenSci006。每组6只大鼠。

Figure 6 Effect of GenSci006 on protein expression of ERα、ERβ、PR in ectopic endometrial tissues of allograft endometriosis rat modelNote： ERα/β， Estradiol receptor α/β； PR， Progesterone receptor. Model group （n=6）， xenografted with endometrial tissues around the uterus and injected with GenSci006 specific solvent； Triptorelin group （n=6）， xenografted with endometrial tissues and injected with 0.25 mg/kg triptorelin； GenSci006-1 and GenSci006-2 groups （each n=6）， xenografted with endometrial tissues and injected with 0.125 mg/kg and 0.25 mg/kg GenSci006， respectively.

参考文献 29

1	中华医学会妇产科学分会子宫内膜异位症协作组. 子宫内膜异位症的诊治指南[J]. 中华妇产科杂志, 2015, 50(3):161-169. DOI: 10.3760/cma.j.issn.0529-567x.2015.03.001 .
	Endometriosis Collaborative Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association. Guidelines for diagnosis and treatment of endometriosis[J]. Chin J Obstet Gynecol, 2015, 50(3):161-169. DOI: 10.3760/cma.j.issn.0529-567x.2015.03.001 .
2	TAYLOR H S, KOTLYAR A M, FLORES V A. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations[J]. Lancet, 2021, 397(10276):839-852. DOI: 10.1016/S0140-6736(21)00389-5 .
3	ALLAIRE C, BEDAIWY M A, YONG P J. Diagnosis and management of endometriosis[J]. CMAJ, 2023, 195(10): E363-E371. DOI: 10.1503/cmaj.220637 .
4	RAFIQUE S, DECHERNEY A H. Medical management of endometriosis[J]. Clin Obstet Gynecol, 2017, 60(3):485-496. DOI: 10.1097/GRF.0000000000000292 .
5	CAPEZZUOLI T, ROSSI M, LA TORRE F, et al. Hormonal drugs for the treatment of endometriosis[J]. Curr Opin Pharmacol, 2022, 67:102311. DOI: 10.1016/j.coph.2022.102311 .
6	KANELLOPOULOS D, KARAGIANNI D, PERGIALIOTIS V, et al. The effect of endometriosis on fertility in an animal model[J]. J Med Life, 2022, 15(9):1170-1175. DOI: 10.25122/jml-2021-0391 .
7	钟瑞华, 周娴颖, 谢淑武, 等. 坤泰胶囊对大鼠实验性子宫异位内膜生长及其妊娠结局的影响[J]. 生殖与避孕, 2015, 1(8):517-524.
	ZHONG R H, ZHOU X Y, XIE S W, et al. Effect of Kuntai capsule on ectopic endometrium and the pregnancy outcome in a rat of endometriosis[J]. Reprod Contracept, 2015, 1(8):517-524.
8	LI H, YANG H D, LU S Y, et al. Autophagy-dependent ferroptosis is involved in the development of endometriosis[J]. Gynecol Endocrinol, 2023, 39(1):2242962. DOI: 10.1080/09513590.2023.2242962 .
9	KARSLıOGLU T, KARASU A F G, YILDIZ P. The effects of micronized progesterone and cabergoline on a rat autotransplantation endometriosis model: a placebo controlled randomized trial[J]. J Invest Surg, 2021, 34(8):897-901. DOI: 10.1080/08941939.2019.1705442 .
10	TEJADA M A, SANTOS-LLAMAS A I, ESCRIVA L, et al. Identification of altered evoked and non-evoked responses in a heterologous mouse model of endometriosis-associated pain[J]. Biomedicines, 2022, 10(2):501. DOI: 10.3390/biomedicines10020501 .
11	VERNON M W, WILSON E A. Studies on the surgical induction of endometriosis in the rat[J]. Fertil Steril, 1985, 44(5):684-694.
12	ZHONG R H, MA A Y, ZHU J P, et al. Kuntai capsule inhibited endometriosis via inducing apoptosis in a rat model[J]. Evid Based Complement Alternat Med, 2016, 2016:5649169. DOI: 10.1155/2016/5649169 .
13	ZHANG J F, ZHU Y, ZHOU X Y, et al. Evaluation of biodegradable microspheres containing nomegestrol acetate in a rat model of endometriosis[J]. Eur J Pharm Sci, 2014, 65:15-20. DOI: 10.1016/j.ejps.2014.08.011 .
14	张薇, 邹移海, 胡海勋, 等. 同种异体移植子宫内膜异位症大鼠模型的建立[J]. 热带医学杂志, 2010, 10(7):770-772.
	ZHANG W, ZOU Y H, HU H X, et al. Establishment of an allograft rat model for the study of endmetriosis[J]. J Trop Med, 2010, 10(7):770-772.
15	孙伟伟, 常欢, 赵瑞华. 活血消异方对子宫内膜异位症大鼠生育力和早期妊娠毒性的影响[J]. 药物评价研究, 2019, 42(4):648-652. DOI: 10.7501/j.issn.1674-6376.2019.04.008 .
	SUN W W, CHANG H, ZHAO R H. Effect of Huoxue Xiaoyi Prescription on fertility and early pregnancy toxicity of rats with endometriosis[J]. Drug Eval Res, 2019, 42(4):648-652. DOI: 10.7501/j.issn.1674-6376.2019.04.008 .
16	崔金秀, 顾振鹏, 刘志慧, 等. 同种异体Sprague-Dawley大鼠子宫内膜异位症动物模型的建立[J]. 中华妇幼临床医学杂志(电子版), 2015, 11(3):388-392. DOI: 10.3877/cma.j.issn.1673-5250.2015.03.022 .
	CUI J X, GU Z P, LIU Z H, et al. Establishment of endometriosis model in allogeneic Sprague-Dawley rats[J]. Chin J Obstet Gynecol Pediatr Electron Ed, 2015, 11(3):388-392. DOI: 10.3877/cma.j.issn.1673-5250.2015.03.022 .
17	崔阳阳, 孙伟伟, 赵瑞华. 子宫内膜异位症动物模型研究进展[J]. 中国实验动物学报, 2013, 21(5):86-89, 94. DOI: 10.3969/j.issn.1005-4847.2013.05.018 .
	CUI Y Y, SUN W W, ZHAO R H. Recent advances in research on animal models of endometriosis[J]. Acta Lab Animalis Sci Sin, 2013, 21(5):86-89, 94. DOI: 10.3969/j.issn.1005-4847.2013.05.018 .
18	TOMAYKO M M, REYNOLDS C P. Determination of subcutaneous tumor size in athymic (nude) mice[J]. Cancer Chemother Pharmacol, 1989, 24(3):148-154. DOI: 10.1007/BF00300234 .
19	UYGUR D, AYTAN H, ZERGEROGLU S, et al. Leflunomide: an immunomodulator: induces regression of endometrial explants in a rat model of endometriosis[J]. J Soc Gynecol Investig, 2006, 13(5):378-383. DOI: 10.1016/j.jsgi.2006.03.006 .
20	唐艳, 张莉, 刘海红. 川芎嗪抑制TLR4/MyD88/NF-κB信号通路减轻子宫内膜异位症大鼠炎症反应[J]. 免疫学杂志, 2023, 39(6):469-477. DOI: 10.13431/j.cnki.immunol.j.20230061 .
	TANG Y, ZHANG L, LIU H H. Ligustrazine mitigates inflammatory response in endometriosis rats by inhibiting TLR4/MyD88/NF-κB signaling pathway[J]. Immunol J, 2023, 39(6):469-477. DOI: 10.13431/j.cnki.immunol.j.20230061 .
21	单婧, 程雯, 翟东霞, 等. 子宫内膜异位症啮齿类动物模型研究进展[J]. 生殖医学杂志, 2017, 26(5):498-501. DOI: 10.3969/j.issn.1004-3845.2017.05.022 .
	SHAN J, CHENG W, ZHAI D X, et al. Research progress of rodent model with endometriosis[J]. J Reprod Med, 2017, 26(5):498-501. DOI: 10.3969/j.issn.1004-3845.2017.05.022 .
22	BERGQVIST A, BERGH T, HOGSTRÖM L, et al. Effects of triptorelin versus placebo on the symptoms of endometriosis[J]. Fertil Steril, 1998, 69(4):702-708. DOI: 10.1016/s0015-0282(98)00019-3 .
23	TESONE M, BILOTAS M, BARAÑAO R I, et al. The role of GnRH analogues in endometriosis-associated apoptosis and angiogenesis[J]. Gynecol Obstet Invest, 2008, 66():10-18. DOI: 10.1159/000148026 .
24	KHAN K N, KITAJIMA M, HIRAKI K, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy[J]. Hum Reprod, 2010, 25(3):642-653. DOI: 10.1093/humrep/dep437 .
25	EMONS G, SCHALLY A V. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers[J]. Hum Reprod, 1994, 9(7):1364-1379. DOI: 10.1093/oxfordjournals.humrep.a138714 .
26	GRÜNDKER C, GÜNTHERT A R, WESTPHALEN S, et al. Biology of the gonadotropin-releasing hormone system in gynecological cancers[J]. Eur J Endocrinol, 2002, 146(1):1-14. DOI: 10.1530/eje.0.1460001 .
27	SUKUMAR J S, QUIROGA D, KASSEM M, et al. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer[J]. Breast Cancer Res Treat, 2021, 190(2):183-188. DOI: 10.1007/s10549-021-06368-4 .
28	郎景和, 冷金花, 王泽华, 等. 促性腺激素释放激素激动剂在子宫内膜异位症和子宫平滑肌瘤治疗中的应用专家意见[J]. 中华妇产科杂志, 2017, 52(2):77-81. DOI: 10.3760/cma.j.issn.0529-567x.2017.02.002 .
	LANG J H, LENG J H, WANG Z H, et al. Expert opinion on the application of gonadotropin-releasing hormone agonist in the treatment of endometriosis and uterine leiomyoma[J]. Chin J Obstet Gynecol, 2017, 52(2):77-81. DOI: 10.3760/cma.j.issn.0529-567x.2017.02.002 .
29	BROWN J, PAN A, HART R J. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis[J]. Cochrane Database Syst Rev, 2010, 2010(12): CD008475. DOI: 10.1002/14651858.CD008475.pub2 .

[1]	秦超, 李双星, 赵婷婷, 蒋晨晨, 赵晶, 杨艳伟, 林志, 王三龙, 文海若. 药物安全评价用SD大鼠90 d喂养试验的背景数据研究[J]. 实验动物与比较医学, 2025, 45(4): 439-448.
[2]	刘力瑜, 嵇波, 刘小玄, 方洋, 张玲, 郭亭廷, 全烨, 李鹤文, 刘翼天. 大鼠胎儿期肺组织固定方法的探索[J]. 实验动物与比较医学, 2025, 45(4): 432-438.
[3]	刘智伟, 杨然, 连浩, 张玉, 金立伦. 秦皮素对碘乙酸钠诱导骨关节炎模型大鼠的软骨保护与抗炎作用[J]. 实验动物与比较医学, 2025, 45(3): 259-268.
[4]	姜萌, 郝淑兰, 仝立国, 仲启明, 高振飞, 王永辉, 王晞星, 吉海杰. 长春瑞滨诱导大鼠足背静脉炎模型的动态评价[J]. 实验动物与比较医学, 2025, 45(3): 251-258.
[5]	肖林林, 杨逸萱, 黎珊杉, 罗兰诗雨, 尹思威, 孙俊铭, 施维, 欧阳轶强, 李习艺. 利用脑立体定位技术将人源三突变APP基因导入海马区构建阿尔茨海默病大鼠模型[J]. 实验动物与比较医学, 2025, 45(3): 269-278.
[6]	潘颐聪, 蒋汶洪, 胡明, 覃晓. 慢性肾脏病大鼠主动脉钙化模型的术式优化及效果评价[J]. 实验动物与比较医学, 2025, 45(3): 279-289.
[7]	连辉, 姜艳玲, 刘佳, 张玉立, 谢伟, 薛晓鸥, 李健. 异常子宫出血大鼠模型的构建与评价[J]. 实验动物与比较医学, 2025, 45(2): 130-146.
[8]	孙效容, 苏丹, 贵文娟, 陈玥. 手术诱导大鼠中重度膝骨关节炎模型的建立与评价[J]. 实验动物与比较医学, 2024, 44(6): 597-604.
[9]	殷玉莲, 马丽娜, 屠思远, 陈玲, 叶媚娜, 陈红风. 非哺乳期乳腺炎大鼠模型的建立及评价[J]. 实验动物与比较医学, 2024, 44(6): 587-596.
[10]	杨劲, 俞诗雅, 林楠, 方永超, 赵虎, 邱锦维, 林鸿铭, 陈惠燕, 王瑜, 吴伟航. 改良型十二指肠旷置术对2型糖尿病大鼠糖代谢的影响[J]. 实验动物与比较医学, 2024, 44(5): 523-530.
[11]	戚龙菊, 陈世园, 廖泽华, 石袁虎, 孙郁雨, 王庆华. 经血干细胞移植联合运动训练促进大鼠脊髓损伤康复的转录组学分析[J]. 实验动物与比较医学, 2024, 44(5): 531-542.
[12]	张乃群, 袁飘漂, 曹琳茸, 应娜, 杨涛涛. PNR检测在糖尿病肾脏疾病模型大鼠诊断及药效评价中的应用[J]. 实验动物与比较医学, 2024, 44(5): 543-549.
[13]	郑艺清, 邓亚胜, 范燕萍, 梁天薇, 黄慧, 刘永辉, 倪召兵, 林江. 基于数据挖掘的盆腔炎性疾病动物模型应用分析[J]. 实验动物与比较医学, 2024, 44(4): 405-418.
[14]	肖攀, 王红义, 陆璐, 张梅, 陈克明, 申栋帅, 牛廷献. 低氧敏感和低氧耐受型Wistar大鼠筛选及其G₁代的低氧敏感性初探[J]. 实验动物与比较医学, 2024, 44(4): 374-383.
[15]	朱晓雨, 袁韩涛, 李四波. 微RNA-887-3p能抑制大鼠椎间盘纤维环细胞中 MDM4表达和细胞增殖并促进细胞凋亡[J]. 实验动物与比较医学, 2024, 44(3): 270-278.

同种异体子宫内膜异位症大鼠模型用于GnRH激动剂类药物的药效评价研究

Application of Allograft Endometriosis Rat Model in Pharmaco-dynamic Evaluation of GnRH Agonists

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 6

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价